Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs Nebius Group NV (NBIS) Price & Performance

Agilent Technologies IncTrade
Nebius Group NVTrade

Price performance (Past 24H)

Key statistics

Agilent Technologies Inc vs Nebius Group NV — how do they compare? Agilent Technologies Inc trades at $149 (market cap $42.00B), while Nebius Group NV trades at $188.85 (market cap $46.75B). The key difference: Agilent Technologies Inc and Nebius Group NV are close in size by market cap, and Agilent Technologies Inc pays a 0.69% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.

ANBIS
Market Cap
$42.00B$46.75B
Sector
HealthTechnology
52-Week High
$157.20$286.69
52-Week Low
$110.24$64.06
Enterprise Value
$43.55B$46.94B
Dividend Yield
0.69%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilent Technologies Inc

Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.

The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.

Nebius Group NV

NBIS trades at $187.97, down 1.01% with a bearish technical signal despite strong analyst support. The stock shows extreme valuation multiples (P/E 71.08, P/S 55.67) while demonstrating explosive revenue growth projections from $530M in 2025 to $878M in 2026. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing, with Q2 2026 results pending. The company faces significant execution risk as it scales AI infrastructure amid substantial capital expenditures.

The investment case hinges on NBIS converting its $1.9B annual run rate and contracted backlog into profitable growth. While analyst consensus remains strongly bullish with a $248.73 price target, high valuation and Michael Burry's short position highlight execution risks. Success depends on managing capex intensity and demonstrating operating leverage in upcoming earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS